|
|
Volumn 21, Issue 18, 2003, Pages 3381-3382
|
|
Will identifying or targeting altered marker expression in response to cytotoxic therapy be of prognostic or therapeutic value?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYCLIN DEPENDENT KINASE INHIBITOR 1;
CYTOTOXIC AGENT;
KI 67 ANTIGEN;
PROTEIN P53;
TUMOR MARKER;
CDKN1A PROTEIN, HUMAN;
CYCLIN DEPENDENT KINASE INHIBITOR 1A;
CYCLINE;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER STAGING;
CANCER SURVIVAL;
CANCER THERAPY;
CLINICAL TRIAL;
COLORECTAL CANCER;
DNA DAMAGE;
EDITORIAL;
GENE MUTATION;
GENE OVEREXPRESSION;
HEAD AND NECK CANCER;
HUMAN;
IMMUNOHISTOCHEMISTRY;
META ANALYSIS;
OVARY CANCER;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN EXPRESSION;
PUBLICATION;
RECTUM CANCER;
SYSTEMATIC REVIEW;
TREATMENT OUTCOME;
BIOSYNTHESIS;
METABOLISM;
NOTE;
RECTUM TUMOR;
TUMOR SUPPRESSOR GENE;
CYCLIN-DEPENDENT KINASE INHIBITOR P21;
CYCLINS;
GENES, P53;
HUMANS;
KI-67 ANTIGEN;
PROGNOSIS;
RECTAL NEOPLASMS;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 0142058039
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2003.04.156 Document Type: Editorial |
|
Times cited : (5)
|
|
References (4)
|
